Does Saxenda help with cravings? Many people considering this prescription weight-loss medication want to know whether it can reduce their desire for food, particularly high-calorie or comfort foods. Saxenda (liraglutide 3.0 mg) is a GLP-1 receptor agonist licensed by the MHRA for weight management in adults and adolescents with obesity. By mimicking a natural gut hormone, Saxenda influences brain pathways that control hunger and satiety. Clinical evidence suggests it can reduce appetite and food cravings, though individual responses vary. This article examines how Saxenda works, what the research shows, and how to maximise its benefits alongside lifestyle changes.

How Saxenda Works to Reduce Appetite and Food Cravings

Saxenda (liraglutide 3.0 mg) is a prescription medicine licensed by the MHRA for weight management in adults with a BMI ≥30 kg/m², or ≥27 kg/m² with at least one weight-related comorbidity. It is also licensed for adolescents ≥12 years with obesity and body weight >60 kg. Saxenda should be used alongside diet and exercise. It belongs to a class of medications called GLP-1 receptor agonists, which mimic the action of glucagon-like peptide-1, a naturally occurring hormone in the body.

GLP-1 is released from the intestines after eating and plays several important roles in appetite regulation. When Saxenda activates GLP-1 receptors in the brain—particularly in areas such as the hypothalamus and brainstem—it influences the neural pathways that control hunger and satiety. This mechanism helps to:

• Reduce feelings of hunger between meals

• Increase feelings of fullness after eating

• Slow gastric emptying, which prolongs the sensation of satisfaction

• Potentially modulate reward pathways associated with food intake

By acting on these multiple pathways, Saxenda can help diminish both physiological hunger and the psychological drive to eat. Many patients report experiencing fewer food cravings, particularly for high-calorie or palatable foods, though individual responses vary considerably.

It is important to understand that Saxenda is not an appetite suppressant in the traditional sense. Rather, it works by restoring more normal appetite signalling in individuals whose regulatory mechanisms may be disrupted due to obesity. The medication is administered once daily via subcutaneous injection, typically starting at a low dose (0.6 mg) and gradually increasing over five weeks to the maintenance dose of 3.0 mg to minimise gastrointestinal side effects. This gradual titration also allows the body to adapt to the appetite-regulating effects of the medication.

Saxenda should not be used concurrently with other GLP-1 receptor agonists.

Clinical Evidence: Does Saxenda Help Control Cravings?

Clinical trial data supports the role of Saxenda in reducing appetite and food cravings, though the evidence specifically examining cravings as a primary outcome is more limited than data on overall weight loss. The pivotal SCALE (Satiety and Clinical Adiposity – Liraglutide Evidence) clinical trial programme demonstrated that patients taking Saxenda experienced significantly greater weight loss compared to placebo, with much of this effect attributed to reduced caloric intake.

In the SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., NEJM 2015), participants receiving liraglutide 3.0 mg lost an average of 8% of their initial body weight over 56 weeks, compared to 2.6% in the placebo group. Patient-reported outcomes from the SCALE programme indicated improvements in control of eating, with reduced hunger scores and increased satiety ratings. Whilst these trials did not specifically measure food cravings using dedicated craving scales, the reduction in hunger and improved eating control suggest an impact on the psychological and physiological drivers of food-seeking behaviour.

Some smaller studies have examined the effects of GLP-1 receptor agonists on food reward and craving responses. Neuroimaging research has shown that liraglutide can reduce activation in brain regions associated with food reward when participants view images of high-calorie foods. This suggests the medication may dampen the hedonic (pleasure-seeking) aspects of eating, not just physiological hunger.

However, it is important to note that individual responses vary considerably. Some patients report dramatic reductions in cravings and food preoccupation, whilst others experience more modest effects. There is no official guarantee that Saxenda will eliminate cravings entirely, and the medication works best when combined with behavioural strategies and dietary modifications. Patients should have realistic expectations and discuss their specific concerns about cravings with their prescribing clinician.

It should be noted that Saxenda is not licensed for the treatment of binge-eating disorder. If you suspect you have binge-eating disorder, discuss this with your healthcare provider as psychological support may be more appropriate.

What to Expect When Taking Saxenda for Weight Management

When starting Saxenda, patients should be prepared for a gradual onset of effects. The medication is not a quick fix, and appetite reduction typically develops progressively as the dose is increased over the first five weeks. Some individuals notice decreased hunger and fewer cravings within the first few weeks, whilst others may require several weeks at the full maintenance dose before experiencing significant benefits.

Common side effects, particularly during the initial titration phase, include:

• Nausea (affecting up to 40% of patients initially)

• Diarrhoea or constipation

• Vomiting

• Headache

• Dizziness

• Abdominal discomfort

These gastrointestinal effects often improve after the first few weeks as the body adjusts. Eating smaller, more frequent meals, choosing bland foods, avoiding high-fat or spicy foods, and staying well hydrated can help manage these symptoms. If side effects are severe or persistent, contact your GP or prescribing clinician, as dose adjustment may be necessary.

According to the Saxenda SmPC and NICE TA664, Saxenda should only be continued if patients achieve at least 5% weight loss after 12 weeks at the maintenance dose. This criterion ensures the medication is providing meaningful benefit. Regular monitoring appointments are essential to assess weight loss progress, manage side effects, and provide ongoing support for dietary and lifestyle changes.

Patient safety considerations include being aware of rare but serious adverse effects. Contact your healthcare provider promptly if you experience:

• Severe, persistent abdominal pain (potential pancreatitis)

• Signs of gallbladder problems (pain in the upper right abdomen, yellowing of skin or eyes)

• Sustained increased heart rate or troubling palpitations

• Signs of depression or suicidal thoughts

Patients with diabetes who take sulfonylureas or insulin may need dose adjustments of these medications to prevent hypoglycaemia when starting Saxenda. Severe vomiting or diarrhoea can lead to dehydration and kidney problems, so maintaining adequate fluid intake is important. Saxenda is not recommended for people with severe gastrointestinal disease, including gastroparesis.

Saxenda must not be used during pregnancy, and should be discontinued if pregnancy is planned or occurs. It is also not recommended during breastfeeding. Women of childbearing potential should use effective contraception while taking Saxenda.

If you experience any suspected side effects, report them to the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk.

Managing Cravings: Saxenda Alongside Lifestyle Changes

Whilst Saxenda can significantly reduce appetite and cravings, optimal results are achieved when the medication is combined with comprehensive lifestyle modifications. The medication should be viewed as a tool that makes it easier to adhere to healthier eating patterns, rather than a standalone solution.

Dietary strategies that complement Saxenda's effects include:

• Eating regular, balanced meals with adequate protein to enhance satiety

• Focusing on nutrient-dense, lower-calorie foods such as vegetables, fruits, whole grains, and lean proteins

• Identifying and managing trigger foods that may still provoke cravings despite medication

• Practising mindful eating to distinguish between true hunger and emotional or habitual eating

• Planning meals and snacks in advance to avoid impulsive food choices

Behavioural approaches are equally important. Cognitive behavioural techniques can help address the psychological aspects of cravings, such as emotional eating or food as a coping mechanism. Many patients benefit from working with a dietitian or participating in a structured weight management programme that addresses both the physical and psychological dimensions of eating behaviour.

Physical activity plays a crucial role in weight management and can help regulate appetite hormones independently of medication. The UK Chief Medical Officers' guidelines recommend that adults aim for at least 150 minutes of moderate-intensity activity per week, though any increase in activity is beneficial. Exercise can also improve mood and reduce stress-related cravings.

It is important to recognise that cravings may not disappear entirely, even with medication. Some degree of desire for palatable foods is normal, and developing strategies to manage occasional cravings without derailing overall progress is part of sustainable weight management. If cravings remain problematic despite Saxenda and lifestyle changes, discuss this with your healthcare provider, as additional psychological support or alternative approaches may be beneficial.

Long-term success with Saxenda requires ongoing commitment to healthy habits. In the NHS, the medication is typically prescribed for up to two years if effective, within specialist weight management services and according to NICE TA664 criteria. Maintaining weight loss after discontinuation depends on the lifestyle changes established during treatment. Regular follow-up with your healthcare team ensures continued support and monitoring throughout your weight management journey.

Frequently Asked Questions